Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

Immuneering Corporation (IMRX) on Monday announced a clinical supply agreement with Eli Lilly and Company (LLY) for the ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Shares of Immuneering rose after the company entered into a clinical supply agreement for Eli Lilly's olomorasib drug to support testing of Immuneering's proposed lung-cancer treatment. The stock was ...

Eli Lilly & Co. is tapping the US investment-grade debt market with a deal that’s expected to include a 40-year bond, a ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Eli Lilly looks attractively valued, with P/E ratios well below historical averages and robust momentum in Zepbound and ...

Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027. At 29 times forward earnings, Lilly stock assumes flawless execution with no ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading ...

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight ...